Siskind D, et al. - The researchers strived to assess the effect of weekly exenatide for weight loss among clozapine-treated obese adults with schizophrenia, with or without type-2 diabetes. For glycaemic control and weight loss, exenatide could be a promising therapeutic agent in clozapine-treated people with obesity. Exenatide could also assist in reducing clozapine-associated cardio-metabolic morbidity and mortality.